REG - e-Therapeutics plc - Total Voting Rights

E-TherapeuticsAnnouncement

29/07/2022 07:01

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220729:nRSc1107Ua&default-theme=true

RNS Number : 1107U  e-Therapeutics plc  29 July 2022

e-therapeutics plc

("e-therapeutics" or the "Company")

 

Total Voting Rights

 

 

 

London, UK, 29 July 2022 - e-therapeutics plc (AIM: ETX; OTCQX; ETXPF), a
specialist in computational drug discovery with a focus on developing RNA
interference ("RNAi") therapeutics, announces that in accordance with the
Financial Conduct Authority's Disclosure and Transparency Rules, the Company
has 514,614,982 ordinary shares of 0.1 pence each in issue, none of which are
held in treasury. Therefore, the total number of voting rights in the Company
is 514,614,982.

The above figure of 514,614,982 may be used by shareholders in the Company as
the denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change in their interest in, the
share capital of the Company.

 

 

Enquiries:

 

 e-therapeutics plc                                 Tel: +44 (0)1993 883 125
 Ali Mortazavi, CEO                                 www.etherapeutics.co.uk
 James Chandler, VP IR & Communications

 SP Angel Corporate Finance LLP                     Tel: +44(0)20 3470 0470
 Nominated Adviser and Broker
 Matthew Johnson/Caroline Rowe (Corporate Finance)
 Vadim Alexandre/Rob Rees (Corporate Broking)

 

 

About e-therapeutics plc

 

e-therapeutics plc is a UK-based company integrating computational power and
biology to accelerate the discovery of life-transforming medicines. The
Company has developed and validated a powerful, disease and modality agnostic
computational approach to drug discovery, leveraging its industry-leading
expertise in network biology to fully capture and interrogate human disease
complexity.

The Company's multi-disciplinary team builds computational models of
biological functions to transform the search for new medicines, interventions,
mechanisms and genetic support. Its biology-led in silico laboratory enables
rapid hypothesis generation and phenotypic screening of millions of compounds
leading to 100-1000x higher hit rates in the wet lab and successful mode of
action elucidation. Novel targets can also be identified, prioritised and
assessed. Harnessing internal target gene discoveries, e- therapeutics is
currently building an in-house pipeline of RNAi based medicines, using its
proprietary GalNAc-siRNA technology.

e-therapeutics has deployed and validated its disease-agnostic computational
drug discovery platform both in house and with partners, including Novo
Nordisk, Galapagos NV, iTeos and a US-based, top 5 pharmaceutical company.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRFZGZNGRZGZZM